COVID Vaccine-Associated Uveitis.

PURPOSE: Following the pandemic of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2, different vaccines were developed and approved by the main medical authorities under emergency protocol regulations. Although highly effective and well-tolerated in most patients, vaccines can uncommonly cause ocular adverse effects. In this article, the current evidence related to vaccine-associated uveitis is reviewed. METHODS: A literature review of uveitis post various SARS-CoV-2 vaccinations. RESULTS: Uveitis was reported following various forms of vaccinations but was more commonly seen following the Pfizer mRNA vaccine which is the most used vaccination worldwide. In western countries, the most common uveitis is mild anterior uveitis, developing within a week of first or subsequent vaccination with good resolution following appropriate topical steroid therapy in most cases. Posterior uveitis and particularly Vogt-Koyanagi-Harada disease was more prevalent in Asia. Uveitis may develop among known uveitis patients and those with other autoimmune diseases. CONCLUSION: Uveitis following Covid vaccinations is uncommon and has a good prognosis.

Coverage of Coronavirus Disease-2019 (COVID-19) Booster Dose (Precautionary) in the Adult Population: An Online Survey.

Background The coronavirus disease-2019 (COVID-19) pandemic devastated public health worldwide, including India. COVID-19 vaccines and their boosters are life-saving developments that have helped prevent and control the spread of COVID-19. We conducted this study to assess the coverage of the booster dose in an Indian population (the third dose of the COVID-19 vaccine in India is referred to as the booster or precautionary dose), record the reasons for not taking the booster dose, and determine the effectiveness of the booster. The levels of adherence to COVID-19 precautionary behavior was also assessed.  Methods We conducted a descriptive, cross-sectional study using convenient sampling via an online survey of 550 respondents older than 18 in the second quarter of 2022. The respondents were distributed among 18 states and union territories in India. The data were analyzed as simple proportions and percentages. Results Of the 550 respondents, 152 (27.6%) received the booster dose, indicating low coverage. A small percentage of respondents (7.2%) reported suffering from COVID-19 following the booster, of whom 91% were medical professionals. The most common reported reason for not taking the vaccine was that the respondents were not yet due for their dose (48.1%). The time between the second dose of the COVID-19 vaccine and the booster had no impact on infection rates. Men were less likely to adhere to COVID-19 precautionary behavior than women, despite similar vaccination rates. Conclusion The COVID-19 vaccine booster had a low acceptance in our study population, with roughly one-quarter of the population receiving the booster. The booster dose has been influential in the prevention of COVID-19. Most respondents followed behavioral safety measures despite the decline of active cases of COVID-19 in India following the Omicron wave. Our results indicate a need to strengthen public strategies to affect behavioral changes, such as improving India's Behavior Change Communication program to ensure adequate booster dose coverage.

COVID-19 vaccination and fertility: fighting misinformation.

The introduction of vaccination against COVID-19 was associated with widespread misinformation on social media concerning, among other things, the potential effect of the vaccine in reducing fertility and increasing the risk of miscarriage among recipients. Tackling misinformation requires an understanding of the context in which it spreads and careful use of the doctor's knowledge and communication skills. Research into ways of tackling disinformation is still at an early stage, but some measures that are likely to be effective include content moderation, misinformation labelling and improving the level of scientific discussion in public media. Health professionals have a duty to provide unbiased and accurate information, including through the use of social media. This requires the maintenance of empathy, trustworthiness and openness in the face of what may at times be malicious intent.

Acute Myocarditis and Pericarditis After mRNA COVID-19 Vaccinations-A Single-Centre Retrospective Analysis.

BACKGROUND: With the rapid rollout of COVID-19 vaccinations, numerous associated and suspected adverse events have been reported nationally and worldwide. Literature reporting confirmed cases of pericarditis and myocarditis following SARS-CoV-2 mRNA vaccinations has evolved, with a predominance in adolescent males following the second dose. METHODS: This was a retrospective analysis of all patients presenting to St Vincent's Hospital, Sydney, Australia with suspected COVID-19 vaccine-related myocarditis and pericarditis. The Brighton Collaboration Case Definitions of Myocarditis and Pericarditis were used to categorise patients into groups based on diagnostic certainty. Cardiac magnetic resonance imaging findings were reviewed against updated Lake Louise Criteria for diagnosing patients with suspected myocarditis. RESULTS: We report 10 cases of confirmed, possible or probable myocarditis and pericarditis. The mean age of presentation in the vaccine group was 33±9.0 years. The most common presenting symptom was pleuritic chest pain (n=8, 80%). Eight patients (80%) had electrocardiogram (ECG) abnormalities (n=6 pericarditis, n=2 myocarditis). Five patients (50%) had a minimum 24 hours of cardiac monitoring. One patient had multisystem inflammatory syndrome following vaccination (MIS-V) with severely impaired left ventricular ejection fraction and required admission to the intensive care unit. DISCUSSION AND CONCLUSION: Cardiac complications post mRNA vaccines are rare. Our case series reflects the worldwide data that vaccine-related myocarditis and pericarditis most frequently occur in young males, following the second dose of the vaccine. These cardiac side effects are mild and self-limiting, with adequate responses to oral anti-inflammatories. One patient developed a severe reaction, with no fatal cases.

COVID-19 and Inflammatory Bowel Disease.

The COVID-19 pandemic caused by the SARS-CoV-2 virus represents an unprecedented global health crisis. Safe and effective vaccines were rapidly developed and deployed that reduced COVID-19-related severe disease, hospitalization, and death. Patients with inflammatory bowel disease are not at increased risk of severe disease or death from COVID-19, and data from large cohorts of patients with inflammatory bowel disease demonstrate that COVID-19 vaccination is safe and effective. Ongoing research is clarifying the long-term impact of SARS-CoV-2 infection on patients with inflammatory bowel disease, long-term immune responses to COVID-19 vaccination, and optimal timing for repeated COVID-19 vaccination doses.

Limits of Tolerance?

In this paper I investigate the limits of toleration using the example of the German debate on dealing with opponents of the covid vaccination. First, I present central elements of Rainer Forst's conception of tolerance. I then refer to an important historical context of the emergence of tolerance and, using Pierre Bayle's conception, show that the demand for tolerance of his time was limited to a specific context, but allows for some generalizations. Finally, I argue that we have to tolerate those who see themselves as "Querdenker" ("lateral thinkers") as long as their opposition does not violate applicable laws and thus endanger the framework of our democratic and constitutional order.

Reactive arthritis after vaccination against SARS-CoV-2: A case series and a mini-review.

The rapid development of COVID-19 vaccines became essential for addressing the global pandemic. Reactive arthritis after vaccination has been a rare phenomenon. Here, we present a case series of three patients with joint inflammation possibly attributed to COVID-19 immunization (mRNA and live adenovirus vectored vaccine). Symptoms were alleviated using non-steroid anti-inflammatory drugs and glucocorticoids. After follow-up, the patients have not been diagnosed with any other rheumatic disease. Reactive arthritis after the COVID-19 vaccine is an unusual adverse effect and poses a negligible risk in comparison to the benefits of immunization, but it should be considered in differential diagnostics by a practicing rheumatologist who cares for patients with new-onset arthritis without apparent cause at the time of pandemic.

Perceived Risks and Perceptions of Covid-19 Vaccination in Patients with Autoimmune Skin Diseases Attending a Tertiary Care Centre in South India: A Questionnaire Based Study

Background: COVID vaccines against the SARS-CoV2 infection helped in reducing the devastating effects of the COVID pandemic. Many studies have portrayed the efficacy and safety of vaccines, there are people who are hesitant to get vaccines due to the fear of side effects and the fear is especially high in patients with autoimmune disorders on systemic immunosuppressant possibly due to lack of awareness and proper counselling. Material(s) and Method(s): This is a cross sectional study done in the Department of Dermatology, Tertiary care centre in India. The study participant who fulfilled the inclusion and the exclusion criteria were included in this study. COVID vaccination details were obtained from 50 patients with autoimmune skin disorders attending the skin OPD. Result(s): Age of the patient ranged from 18 - 70 years in which 45-60 years of the age group were predominant 18(36%)]. The most common autoimmune disease among the study participants was Psoriasis vulgaris 24(48%). Patients taking immunosuppressant were about 20(40%) study participants. About 72% were vaccinated for COVID-19. The most common reason for getting vaccinated is due to its Free of cost (91.6%) followed by confident on the vaccine protection (41.7%). Among those who are not vaccinated, most common reason was found to be ignorance regarding vaccine (64.3%) followed by personal superstitious belief (57.1%). Conclusion(s): Our study concluded that 72% of study population got COVID 19 vaccination and the common reason is due to its free of cost in our country followed by confidence in its efficacy. The rest hesitated due to their personal superstitious beliefs and their ignorance. Overall, during the study period, no major adverse effects related to the vaccine were noted in our study participants. Copyright © 2023, Dr Yashwant Research Labs Pvt Ltd. All rights reserved.

SARS-COV-2 infections in inborn errors of immunity: A single center study.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a single-stranded RNA virus that causes coronavirus disease 2019 (COVID-19). One of the main topics of conversation in these past months in the world of immunology has been the issue of how patients with immune defects will fare if they contract this infection. To date there has been limited data on larger cohorts of patients with Inborn Errors of Immunity (IEI) diagnosed with COVID-19. Here, we review the data of COVID-19 infections in a single center cohort of 113 patients from the Mount Sinai Immunodeficiency program, who had 132 infections between January 2020 and June 2022. This included 56 males and 57 females, age range 2 - 84 (median 42). The mortality rate was 3%. Comparison between admitted patients revealed a significantly increased risk of hospitalization amongst the unvaccinated patients, 4% vaccinated vs 40% unvaccinated; odds ratio 15.0 (95% CI 4.2 - 53.4; p <0.00001). Additionally, COVID anti-spike antibody levels, determined in 36 of these patients post vaccination and before infection, were highly variable.

Nightlife and COVID Vaccinations: A Field Study on an Italian Sample of Party Youth in summer 2021

In this study, we described rates of COVID vaccination, attitudes towards COVID prevention behaviours, and perceived risk in relation to different areas of personal well-being and substance use during the pandemic, in a sample of 16- to 25-year-olds (N= 411). The participants completed a short self-report questionnaire, while they were spending their 2021 summer nightlife in a crowded city venue. Results showed that 64% of respondents reported being vaccinated. Among the unvaccinated participants, those who were unwilling to be vaccinated agreed less with prevention rules and felt more at risk for drug use and for chances of getting or maintaining a job, when compared to both vaccinated peers and to peers who were unvaccinated but positively intentioned to vaccinate. Overall, the present findings confirm that youth felt at risk for their well-being during the pandemic and further reveal that young people who are reluctant to vaccinate deserve more attention. Vaccination campaigns need to be strengthened in social contexts, where chances of getting a job or keeping it are lower, while the risk of drug use is higher.

Breakthrough Sars-Cov-2 infection after Covid-19 vaccination - A retrospective observational clinico-epidemiological study from North-Western India

Introduction: Mass vaccination is considered one of the most crucial weapons in fighting against the ongoing COVID-19 pandemic. However, the occurrence of breakthrough infections (BTIs) has questioned the vaccine effectiveness of the currently available vaccines. The present study aimed to determine the breakthrough SARS-CoV-2 infections in the vaccinated population and to compare the clinic-epidemiological profile and outcomes between breakthrough cases and unvaccinated SARS-CoV-2 positive cases. Methods: This retrospective case-control study was conducted between April 15, 2021, and June 15, 2021, in a zonal military hospital in Jaipur. We evaluated individuals with BTI as cases which were SARS-CoV-2 positive after 14 days of the second dose of vaccine and unvaccinated SARS-CoV-2-positive individuals as control. The clinical and demographic data was collected from the Indian Council of Medical Research and specimen referral forms were filled out for all persons who had undergone testing for SARS-CoV-2. The outcome of positive cases in terms of discharge and deaths were collected from hospital records. Results: A total of 162 breakthrough COVID 19 infections and 925 unvaccinated positive confirmed controls were recorded within the study duration. The majority of cases presented with mild infection in both case (80.2%) and control groups (72.4%). The risk of hospitalization and occurrence of moderate to severe disease was 2.3 and 4 times more in the non-vaccinated group as compared to the vaccinated group, respectively. No mortality was reported among the breakthrough cases. Interpretation and Conclusions: Despite the occurrence of BTIs, the benefits of vaccines are far greater. Our findings suggest that vaccination is associated with a lower risk of hospital admission, severe disease, and mortality against COVID-19. © 2022 Medical Journal of Dr. D.Y. Patil Vidyapeeth ;Published by Wolters Kluwer - Medknow.

Knowledge, attitude, and perception about the utilization of dental services during COVID-19 pandemic among the general population: A cross-sectional survey of an indian subpopulation

Background: The impact of the COVID-19 pandemic made many countries impose lockdown, movement control, or "shelter in place " orders on their residents. The effectiveness of these mitigation measures is highly dependent on the cooperation and compliance of all the members of the population. Many patients were observed to approach dental hospitals and clinics for nonemergency procedures without understanding the risk of contracting the disease. Aim: The aim of this study was to assess the knowledge and attitude about the utilization of dental services during the peak of pandemic. Materials and Methods: An online questionnaire survey was prepared, and answers were collected from 355 participants residing in Tamil Nadu. Results: A total of 355 respondents were included in this preliminary report, and the mean knowledge score was 65.37%. The attitude of most respondents toward instituted preventive measures was satisfactory, with an average attitude score of 71.78%. Conclusion: The majority of the respondents had satisfactory knowledge of the disease, but the knowledge about the spread of infection from the dental office was deficient.

COVID-19 Vaccination: Does It Alter Postoperative Mortality and Morbidity in Hip Fractures?

Introduction The primary aim of our study was to evaluate the impact of coronavirus disease 2019 (COVID-19) vaccination on mortality in patients with hip fractures by comparing it to those who are unvaccinated. Our secondary objective was to compare the impact on postoperative morbidity parameters like length of hospital stay and complications. Methods A total of 619 hip fractures were divided into the 'Vaccinated group' consisting of 300 patients who had COVID-19 vaccination and the 'Unvaccinated group' consisting of 319 patients who were not vaccinated. Patient demographic variables, Nottingham hip fracture score, American Society of Anesthesiologists (ASA) grade, type of anaesthesia used, and Charlson Comorbidity Index were collected. Our primary outcome measures were 30- and 90-day mortality. Secondary outcome measures included postoperative complications like thromboembolic complications, cardiac, and respiratory complications, etc. Mortality among the COVID-positive patients was also compared between the groups. Results Thirty-day postoperative mortality was higher in the unvaccinated group at 13.2% than in the vaccinated group at 5.3%. A similar increase in 90-day mortality was also observed in the unvaccinated group at 24.8% when compared to 14.7% in the vaccinated group(p<0.001). Despite having a higher baseline prevalence of cardiac comorbidities, the Vaccinated group had fewer post-operative cardiac, thromboembolic, and neurological complications (p>0.05). Moreover, electrolyte imbalance and AKI were also seen in fewer patients in the vaccinated group compared to the control group (p<0.05). Furthermore, it was found that among the vaccinated patients who did have perioperative COVID-19 infection, the 30-day mortality was significantly lower (10%) compared to the control group (31.2%) (p<0.001). Similarly, 90-day mortality was significantly lower (25%) compared to the control group (43.75%) (p<0.001). Conclusion Vaccination against COVID-19 independently reduced mortality and morbidity among patients with hip fractures when compared to those who are not vaccinated. Furthermore, it decreased the risk of acquiring COVID-19, and subsequent postoperative complications. Among those who are infected with COVID-19 despite vaccination, the mortality was significantly lesser.

A Case Report: Long Post-COVID Vaccination Syndrome During the Eleven Months After the Third Moderna Dose.

It is undisputed that anti-SARS-CoV-2 vaccines can have side effects. Long post-COVID vaccination syndrome (LPCVS) is one of them and is often neglected. It persists 11 months after the third mRNA-1273 (Moderna) vaccine dose has not been reported. Our patient is a 39-year-old male with a largely uneventful previous history who developed severe adverse reactions immediately after the third dose of the mRNA-1273 (Moderna) vaccine. In addition to brief fever, headache, flickering eyes, skin rashes, tiredness, disorientation, dizziness (brain fog), tiredness, impaired thinking and concentration, and emotional disorders occurred as a result. Cerebral MRI showed non-specific white matter lesions in a frontotemporal distribution. Some of the immune parameters were deflected. Non-steroidal anti-inflammatory drugs, antihistamines, sartans, and statins have occasionally provided temporary relief. In conclusion, LPCVS is a definite complication of anti-SARS-CoV-2 vaccinations and can severely impact the quality of life and lead to disability. Despite extensive work-up, a clear cause for the long-term neuro-cognitive deficits cannot be identified. Symptomatic treatment can provide some relief. Patients with LPCVS should be taken seriously and treated appropriately.

Post COVID Vaccination (COVAXIN™ -BB152 V) Pauci-immune Crescentic Glomerulonephritis.

Coronavirus disease 2019 (COVID-19) pandemic is responsible for widespread morbidity and mortality. The vaccination against the severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection, the cause of the COVID-19 pandemic, is currently ongoing across the globe. Rapid vaccination is of paramount importance to mitigate this pandemic. Although considered safe in general, these vaccines have their share of rare adverse events. We report a case of antineutrophil cytoplasmic antibody (ANCA)-associated pauci-immune crescentic glomerulonephritis 15 days post 2nd dose of a killed COVID-19 (COVAXIN™ -BB152 V) vaccine. We hypothesize that vaccination triggered a systemic immune response in a susceptible patient to develop ANCA-associated vasculitis (AAV), leading to rapidly progressive glomerulonephritis (RPGN).

Reversible Autoimmune Cardiomyopathy Secondary to a Vaccine-Induced Multisystem Inflammatory Syndrome.

The Dominican government started an early booster protocol, including a heterogeneous vaccination sequence needed based on availability. We report a case of a 25-year-old male who presented with jaundice, and vomiting for 6 days, associated with maculopapular rash (Mucocutaneous features), elevated pro-B-type natriuretic peptide (pro-BNP), erythrocyte sedimentation rate (ESR), transaminitis (> 1000 U/L), thrombocytopenia, echocardiogram evidenced stigmata of heart failure after his third dose of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. He was started on steroids and immunoglobulin therapy for multisystemic organ failure syndrome. A significant improvement was noticed, then was discharge; in the post-discharge clinic, he was asymptomatic, inflammatory markers improved, and the echocardiogram showed a recovered ejection fraction. An accurate anamnesis, including a proper chronologic gathering of the events, is essential to recognize a vaccine-multisystem inflammatory syndrome; its prompt assessment and therapy would directly improve the outcome.

Prioritization of operational research questions on COVID-19 vaccination in the African Region.

Introduction: a year after the start of COVID-19 vaccination, coverage remains very low in the African Region. Different challenges and operational barriers have been documented, but countries will need to supplement the available information with operational research in order to adequately respond to practical questions regarding how best to scale up COVID-19 vaccination. We conducted a survey among immunisation program staff working in the African Region, in order to identify the high priority operational research questions relevant to COVID-19 vaccination. Methods: proposed operational research questions categorized into six topic areas were sent to resource persons, asking them to rate according to the relevance, urgency, feasibility, and potential impact of the research questions on the progress of COVID vaccination. Results: a total of 25 research questions have been given an average weighted rating of 75% or more by the respondents. Nine of these top priority research questions were in the area of demand generation, risk communication and community engagement while 8 questions covered the area of service delivery. Conclusion: countries should plan for and coordinate stakeholders to ensure that relevant operational research is done to respond to the top priority research questions, with a view to influence policies and implementation of strategies.

Acute Myopericarditis After the Third Vaccination of BNT162b2 in a Middle-Aged Man.

Messenger ribonucleic acid (mRNA) vaccines against coronavirus disease 2019 (COVID-19) are highly effective in preventing and decreasing disease severity, but the duration of the effect is attenuated over time and repeated vaccination is required. A 41-year-old Japanese male presented to our hospital with chest pain three days after receiving the third dose of the BNT162b2 mRNA vaccine. After various examinations, such as endomyocardial biopsy and viral polymerase chain reaction (PCR) testing of endomyocardial biopsy tissue, we made the diagnosis of acute myopericarditis associated with booster vaccination. Here, we report a rare case of myopericarditis after booster mRNA vaccination.